Henan Cancer Hospital

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients	Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy	Recruiting	Phase 2	2026-09-09		NCT07710248
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)	Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm	Recruiting	Phase 2 / Phase 3	2025-11-21		NCT06378138

Clinical trials